Spred-3 mutation and Ras/Raf/MAPK activation confer acquired resistance to EGFR tyrosine kinase inhibitor in an EGFR mutated NSCLC cell line

BACKGROUND: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are standard treatment for advanced non-small cell lung cancer (NSCLC). However, the emergence of EGFR-TKIs resistance poses a big challenge to the treatment. Although several resistant mutations have been identified...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Zhiyong, Gong, Fusheng, Liao, Jinrong, Wang, Qiang, Su, Ying, Chen, Chao, Lin, Jinghui, Lin, Ren-Jang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797694/
https://www.ncbi.nlm.nih.gov/pubmed/35117614
http://dx.doi.org/10.21037/tcr.2020.03.05

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797694/
https://www.ncbi.nlm.nih.gov/pubmed/35117614
http://dx.doi.org/10.21037/tcr.2020.03.05

Ejemplares similares